Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Back

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Completed

Open to: FEMALE

Age: 18.0 - N/A

London Bebington Sutton Nottingham Coventry Leeds

Medical Conditions

Endometrial Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2013 Jan 2017

Publications

"Mathews C, Lorusso D, Coleman RL, Boklage S, Garside J. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer. Oncologist. 2022 Dec 9;27(12):1058-1066. doi: 10.1093/oncolo/oyac188. Erratum In: Oncologist. 2023 May 8;28(5):e313. doi: 10.1093/oncolo/oyac250."; "36124638"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : 267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles

Intervention Arm Group : AEZS-108 / zoptarelin doxorubicin;

Intervention Type : DRUG
Intervention Description : 60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles

Intervention Arm Group : doxorubicin/ standard chemotherapy;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Imperial College Healthcare NHS Trust
    London
  • The Clatterbridge Cancer Centre NHS Foundation Trust
    Bebington
    Wirral
    CH63 4JY
  • The Royal Marsden Hospital NHS Foundation Trust
    Sutton
    Surrey
    SM2 5PT
  • Nottingham City Hospital NHS Trust
    Nottingham
    NG5 1PB
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry
    CV2 2DX
  • St James's University Hospital
    Leeds
    LS9 7TF


The study is sponsored by AEterna Zentaris



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT01767155
Last updated 05 July 2018

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top